Phase II Trial of RAD001 in Patients With Refractory Colorectal Cancer
Study is completed and closed.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Philip Gold, M.D.
Swedish Cancer Institute
United States: Food and Drug Administration
|Swedish Cancer Institute||Seattle, Washington 98104|